The newly identified DNA nucleases that can be used to treat thalassemia are the transcription activator-like effector nucleases (TALEN).
These are engineered proteins able to stimulate targeted integration of therapeutic wild-type beta-globin cDNAs to the endogenous beta-globin locus.
